Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Cagrilintidesemaglutide in adults with overweight or obesity and type 2 diabetes (Redefine 2 trial) Summary: This Phase 3a, double-blind, randomized, placebo-controlled trial investigated the efficacy and safety of once-weekly subcutaneous cagrilintidesemaglutide (2.4 mg each) in adults with a BMI of 27 or more and type 2 diabetes
Toxicol Appl Pharmacol 2020: Preclinical safety across species
Subcutaneous or intramuscular injection, typically 1-3 times per week, depending on your goals
The D-Retro-Inverso modification (using D-amino acids in reverse sequence) provides resistance to proteolytic degradation while maintaining the ability to interfere with the target protein interaction
US$ 23.42
US$ 26.53
US$ 24.28
US$ 21.01
US$ 28.43
US$ 22.23
